Spiral Therapeutics is a clinical-stage biotech company focused on developing therapies for inner ear disorders, including hearing loss and balance disorders, and advancing its MICS™ (Minimally-Invasive Cochlear System) drug delivery platform. The company’s lead program, SPT-2101, produced a statistically significant reduction in overall vertigo in patients with Ménière’s disease, and Spiral is preparing for a registrational clinical trial. Spiral’s pipeline also includes neurotrophic approaches and other hearing loss programs enabled by precision cochlear delivery. Recent financing will fund continued development of SPT-2101 and expansion of the MICS™ platform. Spiral announced an R&D collaboration with Advanced Bionics to evaluate sustained local drug delivery at the time of cochlear implantation. The company is based in South San Francisco.

Total raised

$45M

Funding rounds

5

Latest round

Series B

Latest activity

Apr 2026